General MedicationsORALGeneric

ALOGLIPTIN AND METFORMIN HYDROCHLORIDE

Standard Dose

12.5MG/1000MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview ALOGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 210212 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ALOGLIPTIN AND METFORMIN HYDROCHLORIDE Form and strength TABLET; ORAL - 12.5MG/1000MG Sponsor MSN LABORATORIES PRIVATE LTD Submission history Latest submission status date: 2019-11-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALOGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 210212 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ALOGLIPTIN AND METFORMIN HYDROCHLORIDE Form and strength TABLET; ORAL - 12.5MG/1000MG Sponsor MSN LABORATORIES PRIVATE LTD Submission history Latest submission status date: 2019-11-27 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.